Sponsored by:

Molecular Imaging

FAPI-PET/CT shows promise in hepatopancreatobiliary cancers
By Will Morton
FAPI-PET/CT could potentially improve noninvasive cancer staging, and, ultimately, clinical decision making.
August 13, 2026
Shown is a 69-year-old man with a cholangiocarcinoma in the distal common bile duct. F-18 FDG-PET/CT was negative where Ga-68 FAPI-46 PET/CT showed high focal FAPI uptake in the liver hilum and surrounding lymph nodes. a-d: F-18 FDG-PET/CT, e-h: Ga-68 FAPI-46 PET/CT. a, b, e, f: Maximum intensity projections, c, g: axial fusion images, d, h: non-contrast enhanced CT.
Radnostix reports revenue decline in Q2
By AuntMinnie.com staff writers
The company attributed the revenue dip to two voluntary product recalls and the Cobalt-60 hot-cell shutdown.
August 13, 2026
Research Money 400
PET/CT predicts response to neoadjuvant therapy in breast cancer
By Will Morton
Monitoring neoadjuvant therapy response in HER2-positive breast cancer is challenging with existing tools.
August 11, 2026
Ga-68 HER2-PET/CT images before neoadjuvant therapy, at end of second cycle, and before surgery. (A) Baseline scan demonstrated soft-tissue lesion measuring approximately 2.3 × 2.2 cm in upper outer quadrant of left breast, with marked radiotracer uptake and SUVmax of 10.1. (B) At end of second cycle, imaging revealed residual lesion of approximately 2.2 × 1.0 cm in same region, without abnormal radiotracer accumulation. (C) Preoperative imaging demonstrated further reduction in lesion size to approximately 2.0 × 0.6 cm, with no abnormal tracer uptake detected.
ITM receives Complete Response Letter for ITM-11
By AuntMinnie.com staff writers
The FDA stated that it's unable to approve the NDA in its present form.
August 10, 2026
Nuclear Medicine
Lantheus reports increased Q2 revenue following Curium deal
By AuntMinnie.com staff writers
The company reported a 2.7% revenue increase in the second quarter of 2026 compared to the same period in 2025.
August 6, 2026
Stock Exchange 400
Plus Therapeutics rebrands as Cerenome
By AuntMinnie.com staff writers
The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.
August 3, 2026
Cerenome
Curium to acquire Lantheus in $8 billion deal
By AuntMinnie.com staff writers
The combined company would serve oncology, neurology, and cardiology patients across more than 70 countries.
August 3, 2026
Cash Bills
Novartis secures expanded approval for Pluvicto
By AuntMinnie.com staff writers
Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.
July 31, 2026
Prostate Imaging
PET/MRI detects arterial inflammation in prostate cancer patients
By Will Morton
Androgen deprivation therapy (ADT) is widely used in advanced prostate cancer, yet is associated with increased cardiovascular events such as stroke and heart attacks.
July 31, 2026
Representative axial fused F-18 FDG-PET/MRI images and corresponding anatomic MRI images from a patient imaged at baseline and after initiation of androgen deprivation therapy are shown. Each row displays a distinct vascular territory. White arrows indicate focal areas of increased tracer uptake within the arterial wall, where spherical volumes of interest (VOIs) were placed for maximum standardized uptake value (SUVmax) measurement. Additional VOIs were placed in the superior vena cava and inferior vena cava for blood-pool activity sampling. SUVmax values from the arterial VOIs were extracted on the corresponding PET images and normalized to the blood-pool mean standardized uptake value to derive the maximum target-to-background ratio.
Ratio Therapeutics adds to coffers
By AuntMinnie.com staff writers
Both new and existing investors participated in the $70 million series C financing round.
July 31, 2026
Money Pile 400
SNMMI issues analysis of 2027 HOPPS proposed rule
By AuntMinnie.com staff writers
The proposed rule includes several positive code-level changes for nuclear medicine providers.
July 29, 2026
Snmmi
ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Page 1 of 633
Next Page